Rigas farmaceitiska fabrika

  • ISIN: LV0000100782
  • Land: .

Nachricht vom 14.05.2012 | 13:30

CORRECTION: Decisions of Shareholders Meeting


Rigas farmaceitiska fabrika 

14.05.2012 13:30
---------------------------------------------------------------------------

Correction: supplemented decision No.4 - budget and action plan for the year
2012 

                        Decisions of Shareholders Meeting

                                        

Decisions of JSC 'Rīgas Farmaceitiskā fabrika' 11.05.2012. Shareholders meeting:



  1. To elect SIA 'OIR birojs' auditor Olga Ibišova as an auditor of JSC 'Rīgas
     Farmaceitiskā fabrika' for the year 2011
 and to approve annual report for the year 2011 from January, 1 till
     December, 31 of JSC 'Rīgas Farmaceitiskā fabrika' ,
including net turnover 2 252 813 EUR (1 583 286 LVL) and profit   12 277
     EUR (8 628 LVL ) .
  2. To release the JSC 'Rīgas Farmaceitiskā fabrika' Board members from
     responsibility for activity in the year 2011.
  3. To leave JSC 'Rīgas Farmaceitiskā fabrika' profit (dividends)
     undistributed.
  4. To approve budget and action plan of JSC 'Rīgas Farmaceitiskā fabrika' for
     the year 2012,
including increasing net turnover till 2 700 000 EUR  (1 900 000 LVL) and
     increasing ofplanned net profit till 140 000 EUR (100 000 LVL).
  5. To elect 
SIA 'OIR birojs', registration number 40003386018, adress Kaleju street
     14a, Jurmala, auditor Olga Ibišova
 as an auditor of JSC 'Rīgas Farmaceitiskā fabrika' for the year 2012.
  6. To elect as the members of supervisory boards (Council):

Dagmara Aboltina, personal code 290344 - 13065, address Brantkalna street 10-23;

Aksana Berzina, personal code 261064-10100, addresse Brivibas gatve 228 - 46,
Riga; 

Natalja Gorbunova, personal code 131047-11214, address Stabu street 47-7, Riga;

Julija Dmitrijeva, personal code 220780-10303, address Avotu street 33-11, Riga;

Vladimir Ivanikin, personal code 040384-12763, address Rīgā, Ģertrūdes street
91-38. 

  1. To amend the Articles of Association and approve new edition of the JSC
     'Rīgas Farmaceitiskā fabrika' Articles of Association.
  2. To authorize the Board with re-authorization rights to execute all actions
     in connection with registration of Decisions of JSC 'R
īgas Farmaceitiskā fabrika
' 11.05.2012. Shareholders meeting.
  3.  To elect as audition committee the Council of JSC 'Rīgas Farmaceitiskā
     fabrika'.
News Source: NASDAQ OMX



14.05.2012 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Rigas farmaceitiska fabrika
              
               
              Latvia
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         LV0000100782
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

Anleihe im Fokus

Die DF-Anleihe 7,875%

Mit der DF Forfait AG vom wachsenden Welthandel profitieren

- Zeichnungsfrist: 21.05. bis 24.05.2013
- Laufzeit: 7 Jahre
- Kupon: 7,875% p.a.
- Volumen: bis zu 30 Mio. Euro
- ISIN: DE000A1R1CC4

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

HELMA Eigenheimbau AG: Kaufen

Die HELMA Eigenheimbau AG präsentierte für das Geschäftsjahr 2012 Rekordwerte. Auf Basis unseres DCF-Modells haben wir einen fairen Wert je Aktie von 22,75 € ermittelt. Ausgehend vom erwarteten 2013er-EPS von 1,64 € entspricht dies einem KGV von 8,4. Das Kurspotenzial beläuft sich auf nahezu 65%.

Aktueller Webcast

Allianz SE

Analysts' conference call on 1Q 2013

15. Mai 2013

Aktuelle Research-Studie

Original-Research: Plan Optik AG (von GBC AG): Kaufen Plan Optik AG

17. Mai 2013